At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIAF bioAffinity Technologies, Inc.
Market Closed 11-22 16:00:00 EST
1.22
-0.01
-1.21%
盘后1.20
-0.02-1.64%
19:39 EST
High1.26
Low1.20
Vol78.17K
Open1.20
D1 Closing1.24
Amplitude4.95%
Mkt Cap19.01M
Tradable Cap10.62M
Total Shares15.58M
T/O96.35K
T/O Rate0.90%
Tradable Shares8.71M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
bioAffinity Technologies Reports $2.4M Revenue For Q3 2024; Expanded CyPath Lung Test Sales To Physicians In Illinois, Alabama, And Louisiana; Now Receiving Orders From Physicians In 11 States
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.